Children's Oncology Group

Leading Statewide Oncology Practice Florida Cancer Specialists Appoints Executive Board Members

Retrieved on: 
월요일, 1월 4, 2021

The oncology landscape is rapidly evolving, and I look forward to partnering with our new Executive Board members to advance the mission of Florida Cancer Specialists in bringing leading treatments, terrific physicians and high-quality care to the doorsteps of more Floridians in their communities.

Key Points: 
  • The oncology landscape is rapidly evolving, and I look forward to partnering with our new Executive Board members to advance the mission of Florida Cancer Specialists in bringing leading treatments, terrific physicians and high-quality care to the doorsteps of more Floridians in their communities.
  • Dr. Michael Diaz, FCS Assistant Managing Physician, added, We extend our sincere appreciation to our outgoing Executive Board members.
  • About Florida Cancer Specialists & Research Institute, LLC: ( FLCancer.com )
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

St. Baldrick's Foundation Supports New Treatment Discovered by Children's Oncology Group and NRG Oncology for Soft Tissue Sarcoma

Retrieved on: 
화요일, 7월 28, 2020

LOS ANGELES, July 28, 2020 /PRNewswire/ -- Research led by the Children's Oncology Group (COG) and NRG Oncology , and supported by the St. Baldrick's Foundation , discovered that adding pazopanib, a type of chemotherapy, to preoperative chemoradiotherapy improves response to treatment for soft tissue sarcoma patients, compared with chemoradiotherapy alone.

Key Points: 
  • LOS ANGELES, July 28, 2020 /PRNewswire/ -- Research led by the Children's Oncology Group (COG) and NRG Oncology , and supported by the St. Baldrick's Foundation , discovered that adding pazopanib, a type of chemotherapy, to preoperative chemoradiotherapy improves response to treatment for soft tissue sarcoma patients, compared with chemoradiotherapy alone.
  • Soft tissue sarcomas represent 7% of childhood and 2% of adult cancers, excluding rhabdomyosarcoma, gastrointestinal stromal tumor and Ewing sarcoma, each of which has a disease-defined treatment.
  • Surgery, with or without radiotherapy, is a common treatment for the 60% of patients with soft tissue sarcoma with small and superficial tumors.
  • The Children's Oncology Group (COG), a National Cancer Institute supported clinical trials group, is the world's largest organization devoted exclusively to childhood and adolescent cancer research.

New Jersey's First National Cancer Institute Community Oncology Research Program (NCORP) Awarded to Atlantic Health Cancer Consortium

Retrieved on: 
목요일, 8월 22, 2019

MORRISTOWN, N.J., Aug. 22, 2019 /PRNewswire/ -- The National Cancer Institute (NCI) has designated Atlantic Health System as a National Community Oncology Research Program (NCORP) site of the Atlantic Health Cancer Consortium (AHCC).

Key Points: 
  • MORRISTOWN, N.J., Aug. 22, 2019 /PRNewswire/ -- The National Cancer Institute (NCI) has designated Atlantic Health System as a National Community Oncology Research Program (NCORP) site of the Atlantic Health Cancer Consortium (AHCC).
  • Atlantic Health System leadership includes experienced cancer investigators in both adult and pediatric cancers with unique expertise that span the cancer continuum.
  • The Atlantic Health Cancer Consortium Community Oncology Research Program (AHCC CORP) is the first and only New Jersey-based National Cancer Institute (NCI) Community Oncology Research Program (NCORP).
  • Atlantic Health System leads the Healthcare Transformation Consortium, a partnership of seven regional hospitals and health systems dedicated to improving access and affordability.

CISCRP Health Communication Services Team to Develop Template for Cancer Clinical Trials Summaries

Retrieved on: 
수요일, 5월 8, 2019

SWOG Cancer Research Network, an NCTN member, initiated the project to make their trials more accessible to the public.

Key Points: 
  • SWOG Cancer Research Network, an NCTN member, initiated the project to make their trials more accessible to the public.
  • The template will be groundbreaking; No NCTN group currently has documented guidelines on how to describe their active cancer trials in plain language.
  • Clinical trials are often the only way cancer patients can get access to cutting-edge cancer treatments, such as immunotherapies.
  • The groups that comprise the NCTN include Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, SWOG Cancer Research Network, and their partners at Canadian Cancer Trials Group.